Loading...
•
Jun 30, 2020
Exact Sciences Q2 2020 Earnings Report
Announced second quarter 2020 results, demonstrating revenue growth despite screening revenue decrease and highlighting precision oncology and COVID-19 testing revenue.
Key Takeaways
Exact Sciences Corp. reported revenue of $268.9 million for the second quarter ended June 30, 2020, compared to $199.9 million for the same period of 2019. Screening revenue decreased by 34 percent, while Precision Oncology and COVID-19 testing contributed $103.0 million and $34.6 million, respectively. The company's net loss was $86.1 million, or $0.58 per share.
Total revenue reached $268.9 million, an increase from $199.9 million in the same period last year.
Screening revenue experienced a 34% decrease.
Precision Oncology revenue was $103.0 million.
COVID-19 testing revenue contributed $34.6 million.
Exact Sciences
Exact Sciences
Exact Sciences Revenue by Segment
Revenue by Segment
Screening Revenue
CapyFin.comPrecision Oncology Revenue
CapyFin.comRevenue & Expenses
Visualization of income flow from segment revenue to net income